Founded in 1988, WEGO started a disposable infusion sets business with tax revolving fund of RMB 25,000. At present, it works on developing medical devices and pharmaceuticals as its main business, while expanding the architectural engineering, finance and other businesses. With more than 80 subsidiaries, 2 listed companies, and more than 30,000 employees, WEGO Holding Co., Ltd., which covers an area of more than 6 million square meters, consists of WEGO Group, WEGO Architecture Engneering Group and WEGO Financial Holding Group. WEGO has 12 industry groups including medical products, blood purification, orthopedics, pharmacy, medical commercial, Shengji, Prifills, Jierui blood technology, medical engineering, medical robot. Main businesses of the architecture engneering group include the real estate, building materials, hotels, food and tourism; main businesses of the financial holding group are asset and fund management, credit, equity investment, and securities management. Main products of WEGO are infusion sets, syringes, blood transfusion equipment, intracardiac consumables, IV catheters and special needles, blood purification equipment and consumables, orthopedic materials, operating equipment and accessories, trauma care, surgical robots, minimally invasive devices and equipment, ICU products and accessories, high-capacity injections and other pharmaceuticals, renal products, biological diagnostic reagents, surgical sutures, dental implants, sense control equipment and consumables, PVC & non-PVC materials and so on. With more than 1000 varieties of products provided in more than 150,000 specifications, WEGO’s medical instruments now have entered into 11 fields out of 15 segmented markets, becoming one of the most safe and reliable suppliers of medical system solutions in the world. WEGO has won many honorary titles such as Industrialization Base of Achievements of National High-tech R&D Program of China (863 Program), National Torch Plan Key High-Tech Enterprise, National Intellectual Property Demonstration Enterprise, Leading Enterprise of China's Industry, Top 500 Chinese Enterprises, Top 500 China Credit Enterprises, Top 500 Private Enterprises in China, National Contract Abiding and Trustworthy Enterprise, National Independent Innovation Demonstration Unit, National May 1st Labor Certificate, China Grand Awards for Industry, National Advanced Enterprise Applying Excellence Performance Model, Shandong Governor Quality Award, Chinese Quality Award Nomination and Global Performance Excellence Award. Weihai Blue Ocean Bank Co., Ltd. is approved to operate by the China Banking Regulatory Commission. In 2020, it ranked No. 375 among the top 500 Chinese enterprises, No. 176 among the top 500 Chinese manufacturing enterprises and No. 92 among the top 500 private manufacturing enterprises.

Shandong Wego Interventional Medical Technology Co., LTD., founded within Weihai high-tech science park, which is a subsidiary industrial group under Wego Group Co., LTD. , with approximately 400 employees by now. The industrial group is mainly engaged in the production and operation of interventional devices and consumables.

The industrial Group consists of Shandong Visee Medical Device Co., LTD., Weihai Wego Medical Devices Co., Ltd. , Weihai Gaowei Medical Equipment Co. , Ltd.,Shenzhen Kinhely Bio-Tech Co.,Ltd., Shandong HuaAn Biotechnology Co., Ltd, Shandong Zurich Medical Technology Co., Ltd. and etc. The primary industrial group products cover interventional devices and consumables for coronary interventional therapy, congenital heart disease, cerebrovascular disease, digestive tract and other non-vascular diseases, peripheral vascular diseases and cardiac electrophysiological diseases. Marketed products include cardic stent, balloon, guide wire, heart occluders, filter, non-vascular stents, detachable coil, micro guide wire; central venous catheter, disposable blood pressure transducer and other products.


Through advanced and reliable global technology platform, we provide patients with a wide range of various urgently needed vascular interventional products.